ABBOTT PARK, Ill., March 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated ...

ABBOTT PARK, Ill., Oct. 28, 2022 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, named Abbott's FreeStyle Libre ® continuous ...

Following a major sales bump in the second quarter of 2019, Abbott Laboratories is planning to significantly ramp up manufacturing for its FreeStyle Libre continuous glucose monitoring system, the ...

The study was carried out at 24 clinical sites across the UK and included 303 participants.

Data from Abbott’s REFLECT study show for the first time that the use of its continuous glucose monitoring technology, Freestyle Libre, can help lessen the severity of cardiovascular complications in ...

A manufacturing problem in millions of Abbott glucose sensors has been tied to at least seven deaths and hundreds of injuries worldwide.

Abbott Laboratories (NYSE:ABT) reported new FreeDM2 trial results on its FreeStyle Libre continuous glucose monitoring system ...

Abbott’s continuous glucose monitoring system, the FreeStyle Libre 2, has been approved in Canada for adults and children four years and older with diabetes. The FreeStyle Libre 2 system continuously ...

The Freestyle Libre 14 day is now the longest-lasting self-applied continuous glucose sensing technology available and allows the used to wear the sensor for up to 14 days with high accuracy. ABBOTT ...

Abbott has now identified the manufacturing issue that caused the fault in the sensors used in its FreeStyle Libre 3 and Libre 3 Plus CGMs. Image credit: Jonathan Weiss via Shutterstock.com. Abbott ...

Patients alarmed after glucose monitors used by diabetics are recalled after links to 7 deaths - Abbott recalled certain sensors used in its FreeStyle Libre 3 and FreeStyle Libre 3 Plus systems, warni ...